PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret®) in patients with severe CAPS
نویسندگان
چکیده
Introduction Anakinra is a recombinant, non-glycosylated form of the human IL-1 receptor antagonist, which recently was approved in US for neonatal onset multisystem inflammatory disease (NOMID), the most severe form of the Cryopyrin-Associated Periodic Syndromes (CAPS). This autoinflammatory disease can be effectively controlled by daily subcutaneous administrations of Kineret[1-3]. The recommended initial dose is 1-2 mg/kg/day and the average maintenance dose is 3-4 mg/kg/day.
منابع مشابه
The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
Introduction CAPS is a rare monogenic autoinflammatory syndrome consisting of a spectrum of three conditions: Familial cold autoinflammatory syndrome (FCAS), MuckleWells syndrome (MWS), and the most severe form, NOMID/CINCA. Progressive hearing loss is a characteristic of severe CAPS [1]. Previous analyses showed that long-term anakinra treatment stabilized the progression of hearing loss [2,3]...
متن کاملPW02-039 - Long-term anakinra treatment in CAPS: a metaanalys
Introduction The common denominator in CAPS (FCAS, MuckleWells syndrome, NOMID/CINCA) is an uncontrolled IL-1b release. An often complete response after treatment with the IL-1 blocker anakinra (Kineret) has been demonstrated in all three entities of CAPS [1-3]. However, the overall documentation is limited due to the inherent difficulties in conducting randomized studies in the more severe for...
متن کاملLong-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
OBJECTIVE Anakinra is approved for the treatment of RA and cryopyrin-associated periodic syndromes (CAPS). While the anakinra safety profile is well established in RA, the long-term safety profile in severe CAPS is less well documented and will therefore be discussed in this report. METHODS A prospective, open-label, single centre, clinical cohort study was conducted at the National Institute...
متن کاملExperience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis
Methods 10 patients (3–17 yrs) with sJIA were enrolled onto a 12 week study at our institution. All patients fulfilled the ILAR classification for sJIA. Out of the 10 patients, 9 had failed anti-TNF. All patients received Anakinra at 2 mg/kg/ day subcutaneously with their current therapy, except anti-TNF. Responders met Definition of Improvement (DOI) criteria by >30% improvement in at least 3 ...
متن کاملBringing the clinical experience with anakinra to the patient.
The recombinant interleukin-1 receptor antagonist, anakinra (Kineret; Amgen Inc., Thousand Oaks, CA), has been approved by the US Food and Drug Administration and the European Commission for the treatment of patients with active rheumatoid arthritis (RA). Approval was granted following the extensive evaluation of anakinra in five pivotal clinical trials that assessed its efficacy and safety in ...
متن کامل